The 9th RNA-Targeted Drug Discovery & Development Summit brings together the leaders advancing RNA-targeted small molecules from early discovery through clinical development. Join senior decision-makers, technical experts, and scientific innovators from biotech, pharma, and academia to uncover the latest advances in RNA-targeted therapeutics.

Large Pharma Leaders

For organizations evaluating RNA-targeted small molecules as the next therapeutic modality.

Key companies include: AstraZeneca, Sanofi, Pfizer, Novartis, Eli Lilly, Astellas, Chugai, Daiichi Sankyo.

Large Pharma Leaders Audience Question

Biotech Decision-Makers

Join the executive leaders accelerating the next generation of RNA-targeted therapeutics and discover where the field is headed next.

Key companies include: Remix Therapeutics, PTC Therapeutics, ReviR Therapeutics, Sanofi, Pfizer, Ribonaut Therapeutics, Atomic AI, Dewpoint Therapeutics, EPICS Therapeutics, AstraZeneca, Ribometrix, Arrakis Therapeutics.

Biotech Leaders Watching

Biotech Drug Developers

For companies building RNA-targeted small molecule platforms and pipelines.

Key companies include: Remix Therapeutics, ReviR Therapeutics, Arrakis Therapeutics, Ribometrix, Ribonaut Therapeutics, Dewpoint Therapeutics, Syrna Therapeutics, Renasis Bio, RevoNA Bio.

Biotech Drug Developers

Discovery & Translational Scientists

For technical experts developing the next generation of RNA-targeted therapeutics.

Key functions include: RNA Biology, Medicinal Chemistry, Drug Discovery, Screening, Structural Biology, Computational Biology, and Translational Sciences.

Scientist Networking

Academic & Research Pioneers

For researchers advancing understanding of RNA structure, biology and druggability.

Institutions include: UNC Chapel Hill, University of Toronto, University of Colorado Boulder, University of Wisconsin–Madison and many more.

Academics Discussing

Turn RNA Innovation Into Action

From identifying functional RNA targets and optimizing lead compounds to securing strategic partnerships and evaluating new modalities, this summit is designed to help you overcome the challenges facing the next generation of RNA-targeted therapeutics.

Explore the latest scientific advances, connect with peers facing similar challenges, and leave with practical insights you can immediately apply to your research, pipeline, and business strategy.

Secure your place today or explore the full agenda to discover the sessions most relevant to you.